Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 26, 1996 - Issue 8
29
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Captopril methylation in human liver and kidney: interindividual variability

, , , , &
Pages 877-882 | Received 01 Dec 1995, Published online: 22 Sep 2008
 

Abstract

1. The methylation of captopril was studied in the microsomal fraction obtained from 87 specimens of human liver and 70 specimens of human renal cortex.

2. The rate of captopril methylation ranged over one order of magnitude in the liver and kidney. In the human liver, the mean (± SD) rate of captopril methylation (pmol/min/mg) was significantly (p < 0·001) greater women (199 ± 97) than in men (126 ± 88), whereas in the kidney no sex-difference was observed, and the mean (± SD) of all cases was 47 ± 23 pmol/min/mg.

3. In the kidney, the statistical analysis revealed the presence of two subgroups in the rate of captopril methylation and their mean (± SD) estimates were 42·5 ± 13·9 and 90·3 ± 12·0 pmol/min/mg (p < 0·05). Of the population, 84 % fell in the former and the remaining 16 % in the latter subgroup.

4. Captopril is mainly eliminated by metabolism and its bioavailability is 65 %. Methylation is one of the metabolic routes of captopril and its variability may contribute, to some extent, to modulate the intracellular concentration of this drug.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.